AstraZeneca Halts Second Phase III Trial of Prostate Cancer Drug Zibotentan

AstraZeneca has halted a second Phase III trial studying zibotentan monotherapy in patients with non-metastatic castrate-resistant prostate cancer (CRPC) due to a lack of efficacy. Results from an early efficacy review conducted by an independent data monitoring committee showed zibotentan monotherapy was not going to meet its primary efficacy endpoints of progression-free survival and overall survival, making it doubtful the drug would benefit patients with non-metastatic CRPC, the company said.
Drug Industry Daily